Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 12 months. But with a 3.5% pullback in the past month, all eyes are now on its first-quarter report, expected to drop shortly on May 5, after market hours.Alyftrek and Journavx — The Two Big LaunchesAccording to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company’s two big launches: Alyf ...